Tech Company Financing Transactions
Everest Biolabs Funding Round
Everest Biolabs, based in Waltham, received $2.1 million from National Institutes of Health.
Transaction Overview
Company Name
Announced On
9/24/2026
Transaction Type
Debt
Amount
$2,100,000
Round
Undisclosed
Investors
Proceeds Purpose
The grant will support the development of next-generation, automated, plate-based EV isolation technology, aimed at a central problem in clinical proteomics: the proteins that carry the most diagnostic information in blood are buried beneath those that carry the least.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
204 Second Ave 102
Waltham, MA 02451
USA
Waltham, MA 02451
USA
Phone
Website
Email Address
Overview
Everest Biolabs delivers excellence in extracellular vesicle (EV) research through a relentless focus on quality and easy-to-use tools for EV isolation and analytics, built to enhance your daily workflows and propel the field to new heights. Every column, assay, and instrument we make is designed to deliver reproducible results you can build on. With scientific rigor at the heart of our work, we help you move confidently from sample to insight.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
George Daaboul
Chief Operating Officer
David Freedman
Co-Founder
Dima Ter-Ovanesyan
Co-Founder
David Walt
VP - Manufacturing
Trey Wheelahan
VP - Product Management
Steven Scherr
VP - R & D
Tal Gilboa
VP - Sales
Dimitri Aubert
Browse more venture capital transactions:
Prev: 9/24/2026: Chari venture capital transaction
Next: 9/24/2026: Dextr AI venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs